Selected article for: "antiviral activity and FIPV infectious peritonitis virus"

Author: Dong, Wanyu; Xie, Wenting; Liu, Yunbo; Sui, Baokun; Zhang, Hao; Liu, Liran; Tan, Yubei; Tong, Xiaohan; Fu, Zhen F.; Yin, Ping; Fang, Liurong; Peng, Guiqing
Title: Receptor tyrosine kinase inhibitors block proliferation of TGEV mainly through p38 mitogen-activated protein kinase pathways
  • Cord-id: 40bshqly
  • Document date: 2019_11_18
  • ID: 40bshqly
    Snippet: Emerging coronaviruses (CoVs) primarily cause severe gastroenteric or respiratory diseases in humans and animals, and no approved therapeutics are currently available. Here, A9, a receptor tyrosine kinase inhibitor (RTKI) of the tyrphostin class, is identified as a robust inhibitor of transmissible gastroenteritis virus (TGEV) infection in cell-based assays. Moreover, A9 exhibited potent antiviral activity against the replication of various CoVs, including murine hepatitis virus (MHV), porcine e
    Document: Emerging coronaviruses (CoVs) primarily cause severe gastroenteric or respiratory diseases in humans and animals, and no approved therapeutics are currently available. Here, A9, a receptor tyrosine kinase inhibitor (RTKI) of the tyrphostin class, is identified as a robust inhibitor of transmissible gastroenteritis virus (TGEV) infection in cell-based assays. Moreover, A9 exhibited potent antiviral activity against the replication of various CoVs, including murine hepatitis virus (MHV), porcine epidemic diarrhea virus (PEDV) and feline infectious peritonitis virus (FIPV). We further performed a comparative phosphoproteomic analysis to investigate the mechanism of action of A9 against TGEV infection in vitro. We specifically identified p38 and JNK1, which are the downstream molecules of receptor tyrosine kinases (RTKs) required for efficient TGEV replication, as A9 targets through plaque assays, qRT-PCR and Western blotting assays. p38 and JNK1 inhibitors and RNA interference further showed that the inhibitory activity of A9 against TGEV infection was mainly mediated by the p38 mitogen-activated protein kinase (MAPK) signaling pathway. All these findings indicated that the RTKI A9 directly inhibits TGEV replication and that its inhibitory activity against TGEV replication mainly occurs by targeting p38, which provides vital clues to the design of novel drugs against CoVs.

    Search related documents:
    Co phrase search for related documents
    • activity assess and low effect: 1
    • acute diarrhea and addition time: 1
    • addition time and log reduction: 1
    • addition time and low effect: 1
    • loading buffer and lysis buffer: 1, 2, 3, 4, 5, 6
    • loading control and lysis buffer: 1, 2, 3, 4, 5
    • log reduction and low effect: 1